Our Assets
AlphaOnco Group at a glance
Innovative thermal treatment of prostate cancer
using magnetosomes and moderate-intensity ultrasound
Sole manufacturer of magnetosome nano-minerals
Unique first-in-class innovative medical device,
based on hyperthermia, enabling to eradicate solid tumors, starting with the treatment of prostate tumors
Strong team mixing scientific and business skills
supported by renowned experts
Preclinical efficacy shown on different tumor types
(prostate, breast, glioblastoma, sarcoma) and animal models (mice & dogs)
Market potential exceeding €300m for prostate cancer
€1bn+ potential when considering all solid tumors (including breast cancer, etc.)
3 success factors :
AlphaOnco is the only company in the world that controls magnetosome fabrication for therapeutic uses.
Devices used in treatment (magnetosomes + ultrasound heating probe) and associated methods of treatment protected worldwide by 13 patent families.
Treatment developed by AlphaOnco presents unique features:
It is simple, minimal invasive, does not require general anesthesia, nor use of operation theatre, nor prostate removal, and can be carried out on an outpatient basis.
As of today, prostate cancer treatment techniques such as surgery or radiotherapy are invasive and require hospital, a radiotherapist and a surgeon, and may cause side effects such as impotency or lead to prostate removal.
€8.9m raised since inception to conduct successfully first preclinical studies, with a complement of € 3.5m invested in 2024 by an investment company: EP Equity Investment, owned by Daniel Křetínský.
Raising €10m to cover the preparation of the clinical trials (from 2026 onwards): focusing on fabrication of magnetosomes at large scale and regulatory toxicity/ biocompatibility tests.
Key KPIs
Collaborations
AlphaOnco collaborates with several companies and laboratories in France and abroad.
Team members
(3 FTEs, scientific/medical advisers, consultant & PhD students)
Cost effective, high level & multidisciplinary team.
13 patents families
Very strong patent portfolio: 4th largest one according to Marks & Clerk.
+40 publications
High scientific impact: E. Alphandéry ranked 1st in iron oxide nanoparticle specialty.